Shots:
- Zydus has reported topline P-IIb/III (EPICS-III) trial results in PBC pts resistant or intolerant to ursodeoxycholic acid (UDCA), where pts were randomized to Saroglitazar (1mg) or PBO, following optimal dose selection
- Trial met its composite 1EP, showing a 48.5% treatment difference in biochemical response, & also achieved its key 2EP with a higher proportion of pts achieving complete ALP normalization (ALP <ULN) at 52wks.; data to be presented at a future conference
- Additionally, Saroglitazar (PPAR α/γ agonist) is planned for submission to the US FDA in Q1’26
Ref: Zydus | Image: Zydus | Press Release
Related News:- BeOne Medicines Reports Topline P-III (BGB-11417-201) Trial Data on Sonrotoclax in R/R Mantle Cell Lymphoma (MCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
